-
公开(公告)号：CA2655289A1
公开(公告)日：2007-12-27
申请号：CA2655289
申请日：2006-08-24
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： NAKATSURU SHUICHI , KATAGIRI TOYOMASA , NAKAMURA YUSUKE , ENDO KEIGO
IPC: C07K16/30 , A61K39/395
Abstract: The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Als o, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-assoc iated disease; and a method for in vivo imaging of FZD10 in a subject.
-
公开(公告)号：AU2003263603A8
公开(公告)日：2004-04-23
申请号：AU2003263603
申请日：2003-09-17
Applicant: ONCOTHERAPY SCIENCE INC , JAPAN PRESIDENT UNIV TOKYO
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA
Abstract: Objective methods for detecting and diagnosing pancreatic cancer (PNC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of PNC-associated gene that discriminates between PNC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of pancreatic cancer, methods of treating pancreatic cancer and method of vaccinating a subject against pancreatic cancer.
-
公开(公告)号：AU2003260966A8
公开(公告)日：2004-04-23
申请号：AU2003260966
申请日：2003-09-12
Applicant: JAPAN PRESIDENT UNIV TOKYO , ONCOTHERAPY SCIENCE INC
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA
Abstract: Objective methods for detecting and diagnosing pancreatic cancer (PNC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of PNC-associated gene that discriminates between PNC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of pancreatic cancer, methods of treating pancreatic cancer and method of vaccinating a subject against pancreatic cancer.
-
公开(公告)号：AU2003260965A8
公开(公告)日：2004-04-23
申请号：AU2003260965
申请日：2003-09-12
Applicant: UNIV TOKYO , JAPAN PRESIDENT UNIV TOKYO , ONCOTHERAPY SCIENCE INC
Inventor： KATAGIRI TOYOMASA , NAKAMURA YUSUKE
IPC: C12Q1/68
-
公开(公告)号：CA2500470A1
公开(公告)日：2004-04-15
申请号：CA2500470
申请日：2003-08-12
Applicant: ONCOTHERAPY SCIENCE INC , UNIV TOKYO
Inventor： KATAGIRI TOYOMASA , NAKAMURA YUSUKE
Abstract: Objective methods for detecting and diagnosing Chronic myeloid leukemia (CML ) are described herein. In one embodiment, the diagnostic method involves the determining a expression level of CML-associated gene that discriminate between CML and nomal cell. The present invention further provides methods o f screening for therapeutic agents useful in the treatment of CML, methods of treating CML and method of vaccinating a subject against CML.
-
Patent Agency Ranking
公开(公告)号：WO2008018642A3
公开(公告)日：2008-04-03
申请号：PCT/JP2007065992
申请日：2007-08-10
Applicant: ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKATSURU SHUICHI
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKATSURU SHUICHI
CPC classification number: C07K16/18 , A61K31/7088 , C07K14/47 , C07K14/4748 , C12N2310/14 , C12Q1/485 , G01N33/5011 , G01N33/5035 , G01N33/57415 , G01N2333/9121 , G01N2510/00
Abstract: The present application provides novel human genes A7322,
Abstract translation: 本申请提供了新的人类基因A7322，
-
公开(公告)号：WO2007013575A3
公开(公告)日：2007-10-25
申请号：PCT/JP2006314946
申请日：2006-07-21
Applicant: ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKATSURU SHUICHI
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKATSURU SHUICHI
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/136 , C12Q2600/158
Abstract: Objective methods for detecting and diagnosing renal cell carcinoma (RCC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of RCC-associated gene that discriminates between RCC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of renal cell carcinoma, methods of treating renal cell carcinoma and method of vaccinating a subject against renal cell carcinoma.
Abstract translation: 本文描述了用于检测和诊断肾细胞癌（RCC）的客观方法。 在一个实施方案中，诊断方法包括确定区分RCC细胞和正常细胞的RCC相关基因的表达水平。 本发明进一步提供筛选用于治疗肾细胞癌的治疗剂的方法，治疗肾细胞癌的方法以及针对肾细胞癌接种受试者的方法。
-
公开(公告)号：WO2006085684A9
公开(公告)日：2006-10-19
申请号：PCT/JP2006302684
申请日：2006-02-09
Applicant: ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKATSURU SHUICHI
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKATSURU SHUICHI
IPC: C12Q1/68
CPC classification number: C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/57407 , G01N2500/00
Abstract: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. In particular, the present application provides novel human genes C2093, B5860Ns and C6055s whose expression is markedly elevated in bladder cancers. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target molecules for developing drugs against the disease, and for attenuating cell growth of bladder cancer.
Abstract translation: 本文描述了用于检测和诊断膀胱癌（BLC）的客观方法。 在一个实施方案中，诊断方法包括确定区分BLC细胞和正常细胞的BLC相关基因的表达水平。 本发明进一步提供了使用在具有淋巴结转移的膀胱癌细胞中具有独特改变的表达模式的BLC相关基因来预测和预防膀胱癌转移的手段。 最后，本发明提供了筛选可用于治疗膀胱癌的治疗剂的方法，治疗膀胱癌的方法以及针对膀胱癌接种受试者的方法。 具体而言，本申请提供了在膀胱癌中表达显着升高的新型人基因C2093，B5860N和C6055。 由基因编码的基因和多肽可以用于例如膀胱癌的诊断，作为开发针对该疾病的药物的靶分子，以及用于减弱膀胱癌的细胞生长。
-
公开(公告)号：WO2005029067A3
公开(公告)日：2005-08-18
申请号：PCT/JP2004011741
申请日：2004-08-10
Applicant: ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKATSURU SHUICHI
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA , NAKATSURU SHUICHI
IPC: C07K14/47 , C12N9/10 , C12Q1/68 , G01N33/574 , G01N33/48
CPC classification number: C12Q1/6886 , C07K14/4702 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , G01N33/57415 , G01N2500/04
Abstract: Compositions and objective methods for detecting, diagnosing, and treating breast cancer (BRC) are described herein. In particular, the present invention describes three BRC-associated genes, referred to herein as A5657, B9769, and C7965, up-regulated in BRC cells as compared to normal cells. In one embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates between BRC cells and normal cells; in an alternate embodiment, the diagnostic method involves determining the expression level of a BRC-associated gene that discriminates among BRC cells, between DCIS cells and IDC cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of breast cancer, methods of treating breast cancer and methods for vaccinating a subject against breast cancer.
Abstract translation: 本文描述了用于检测，诊断和治疗乳腺癌（BRC）的组合物和客观方法。 特别地，本发明描述了与正常细胞相比，在BRC细胞中上调的三种BRC相关基因（本文称为A5657，B9769和C7965）。 在一个实施方案中，诊断方法包括确定区分BRC细胞和正常细胞的BRC相关基因的表达水平; 在替代实施方案中，诊断方法包括确定区分BRC细胞，DCIS细胞和IDC细胞之间的BRC相关基因的表达水平。 本发明进一步提供了筛选用于治疗乳腺癌的治疗剂的方法，以及用于治疗乳腺癌的方法以及接种受试者抵抗乳腺癌的方法。
-
20.发明申请
公开(公告)号：WO2005029089A3
公开(公告)日：2005-06-02
申请号：PCT/JP2004013718
申请日：2004-09-14
Applicant: ONCOTHERAPY SCIENCE INC , UNIV TOKYO , NAKAMURA YUSUKE , KATAGIRI TOYOMASA
Inventor： NAKAMURA YUSUKE , KATAGIRI TOYOMASA
IPC: G01N33/574 , G01N33/68
CPC classification number: G01N33/689 , G01N2800/364
Abstract: Disclosed are methods of diagnosing ovarian endometriosis using an antibody against the TFPI-2 protein. According to the present invention, this protein is detected at higher levels in the serum of subjects suffering from endometriosis as compared to normal control subjects and thus may serve as diagnostic marker and therapeutic target for ovarian endometriosis. In addition to methods of diagnosing ovarian endometriosis, the present invention provides kits for performing the diagnosis.
Abstract translation: 公开了使用针对TFPI-2蛋白的抗体诊断卵巢子宫内膜异位症的方法。 根据本发明，与正常对照受试者相比，在患有子宫内膜异位症的受试者的血清中检测到该蛋白质较高，因此可作为卵巢子宫内膜异位症的诊断标志物和治疗靶标。 除了诊断卵巢子宫内膜异位症的方法之外，本发明提供用于进行诊断的试剂盒。
-
-
-
-
-
-
-
-
-
Search Results
81
records
(took 0.027 seconds)
